Nasdaq
$0.9173▼ 1.38%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.8MShares out 4.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
34- 3d agoPre-market26.10.22 21:008-KKey event#●●●#●●●
Valion Bio, Inc.
Valion Bio's interim CEO, Dean Zikria, announced the findings of his 30-day strategic review. The company will prioritize accelerating the development of its pipeline, including Entolimod, driving commercial traction for its subsidiary Velocity Bioworks, and evaluating strategic options such as partnerships or a potential sale to maximize shareholder value.…more
$0.9173-1.38%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 4d agoPre-market26.10.21 13:15filedEFFECTOther
Valion Bio, Inc.
Valion Bio, Inc. received SEC effectiveness approval for its registration statement on October 20, 2026. This authorization allows the company to proceed with the issuance and sale of securities as detailed in the filing.…more
$0.9173-1.38%vs prev closeView filingShare - 4d agoPre-market26.10.21 13:15filedEFFECTOther
Valion Bio, Inc.
Valion Bio, Inc.'s registration statement (File No. 333-299506) was declared effective by the SEC on October 20, 2026. This effectiveness allows the company to proceed with the issuance and offering of securities as detailed in the filing.…more
$0.9173-1.38%vs prev closeView filingShare
33 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 21:02#●●●#●●●
Valion Bio Explores Strategic Options Including Sale of Velocity Bioworks…more
Valion Bio is reviewing strategic alternatives for its contract manufacturing unit, Velocity Bioworks, which may include a potential sale. This move indicates a shift toward optimizing the company's business portfolio.…more
$0.9173-1.38%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.15Pre-market26.10.15 21:01
●●●●●●●● ●●●●● ●●●●●●
Valion Bio's subsidiary, Velocity Bioworks, has successfully completed an initial feasibility evaluation of LarmorBio's BioScan-NMR platform. The study confirmed the potential for real-time monitoring to improve efficiency and reduce batch failures in biologics manufacturing.…more
$0.9173-1.38%vs prev closeShareBenzinga - 10.14Pre-market26.10.14 21:19
●●●●●●●● ●●●●● ●●●●●●
Valion Bio announced that its subsidiary, Velocity Bioworks, is offering CDMO services to support biotechnology firms looking for U.S.-based manufacturing. This initiative aligns with the industry's shift toward domestic production following the implementation of new U.S. pharmaceutical tariffs.…more
$0.9173-1.38%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report